UBS reiterates Buy on Revolution stock, keeps $265 price target
UBS maintained a Buy rating and $265 price target for Revolution Medicines (RVMD). The stock has risen 243% in a year to $183.23, though some analysts suggest it is overvalued. Positive clinical trial results for darazonrasib in pancreatic cancer were reported, showing improved survival rates. Multiple analysts have recently upgraded or initiated coverage with positive ratings and price targets ranging from $226 to $318.
How this was made
The 30-second read
Why it matters
The combination of new clinical data and analyst upgrades creates a catalyst for short-term price appreciation.
Market read
Analyst upgrades tied to fresh trial data make RVMD a near-term trade candidate.
What to watch
Potential regulatory hurdles and competition from other RAS inhibitors could temper upside.
Background
Revolution Medicines (RVMD) reported Phase 3 trial results for darazonrasib, showing a hazard ratio of 0.40 versus chemotherapy, and several analysts updated their coverage with higher price targets.
Ticker impact
UBS reiterated a Buy rating on Revolution Medicines and maintained a $265 price target, citing recent Phase 3 trial data showing survival benefit.
likely upside as the market prices in the favorable trial outcomes and higher target prices
Multiple analysts raised price targets and reiterated Buy ratings on the same day the trial data were disclosed, indicating fresh positive sentiment.
Market effects
Positive trial data may boost sentiment in the broader oncology biotech sector.
Limited to U.S. biotech equities.
Modest, as the drug targets a global cancer indication.
Counterpoint
Some investors may question the durability of the survival benefit given wide confidence intervals.
Key entities
- companyRevolution Medicines Inc.
Biotech firm developing RAS-targeted cancer therapies.
- analystUBS
Reiterated Buy rating and $265 target.
